Hendrik-Tobias Arkenau

Hendrik-Tobias Arkenau

UNVERIFIED PROFILE

Are you Hendrik-Tobias Arkenau?   Register this Author

Register author
Hendrik-Tobias Arkenau

Hendrik-Tobias Arkenau

Publications by authors named "Hendrik-Tobias Arkenau"

Are you Hendrik-Tobias Arkenau?   Register this Author

76Publications

1823Reads

36Profile Views

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

J Clin Oncol 2017 Sep 23;35(26):2993-3001. Epub 2017 Jun 23.

Toni K. Choueiri, Dana-Farber Cancer Institute, Boston; Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, and Humphrey Gardner, AstraZeneca, Waltham, MA; Elizabeth Plimack, Fox Chase Cancer Center, Philadelphia, PA; Eric Jonasch, MD Anderson Cancer Center, Houston, TX; Sumanta Kumar Pal, City of Hope, Duarte, CA; Hendrik-Tobias Arkenau, Sarah Cannon Research Institute, University College London Cancer Institute; Thomas Powles, Barts Cancer Institute, London; Shethah Morgan, AstraZeneca, Cambridge, United Kingdom; Daniel Y.C. Heng, Tom Baker Cancer Center, Calgary, Alberta, Canada; and Laurence Albiges, Institute Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2967
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2967DOI Listing
September 2017

Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?

J Clin Oncol 2017 04 23;35(12):1370-1371. Epub 2017 Jan 23.

Mario Uccello, Michele Moschetta, and Hendrik-Tobias Arkenau, Sarah Cannon Research Institute UK, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.0921DOI Listing
April 2017

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.

Exp Hematol Oncol 2017 10;6. Epub 2017 Jan 10.

Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-016-0061-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223353PMC
January 2017

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 06 5;77(6):1275-83. Epub 2016 May 5.

Sarah Cannon Research Institute UK, 93 Harley Street, London, W1G 6AD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3031-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882359PMC
June 2016

Immunotherapy for bladder cancer: rediscovering an old friend.

BJU Int 2016 May 20;117(5):721-4. Epub 2015 Oct 20.

Department of Medical Oncology, Guy's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.13330DOI Listing
May 2016

Patients' perceptions of research biopsies in phase I oncology trials.

Oncology 2015 14;88(2):95-102. Epub 2014 Oct 14.

Sarah Cannon Research Institute, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000368161DOI Listing
April 2015

Clinical impact of checkpoint inhibitors as novel cancer therapies.

Drugs 2014 Nov;74(17):1993-2013

Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, 37203, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-014-0305-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224737PMC
November 2014

Improving patient selection for phase I oncology trials.

J Clin Oncol 2014 Oct 28;32(28):3198-9. Epub 2014 Jul 28.

Sarah Cannon Research Institute UK; and University College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.8031DOI Listing
October 2014

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment.

Melanoma Res 2014 Aug;24(4):408-12

aMedical Professorial Unit, Prince of Wales Hospital and University of New South Wales, Randwick, New South Wales, Australia bSarah Cannon Research UK and University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086757PMC
August 2014

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

World J Gastroenterol 2014 Aug;20(30):10288-95

Pavlina Spiliopoulou, Hendrik-Tobias Arkenau, Drug Development Unit, Sarah Cannon Research Institute United Kingdom, London W1G 6AD, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v20.i30.10288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130836PMC
August 2014

Combination therapies for the treatment of advanced melanoma: a review of current evidence.

Biochem Res Int 2014 12;2014:307059. Epub 2014 Feb 12.

Sarah Cannon Research Institute UK, London W1G 6AD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/307059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944792PMC
June 2014

The future is here: tumour profiling in day-to-day clinical practice.

Drug Discov Today 2013 Aug 22;18(15-16):689-91. Epub 2013 Jun 22.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2013.06.006DOI Listing
August 2013

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.

Drugs 2013 Jun;73(8):767-77

Sarah Cannon Research UK, 93 Harley St, London W1G 6AD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0049-8DOI Listing
June 2013

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

World J Gastroenterol 2012 Nov;18(44):6376-8

Drug Development Unit, Sarah Cannon Research UK, University College London, London W1G 6AD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v18.i44.6376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508631PMC
November 2012

Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.

Clin Med Insights Oncol 2012 5;6:53-66. Epub 2012 Jan 5.

Sarah Cannon Research UK and Cancer Institute, University College London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S5855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256981PMC
August 2012

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence.

Ther Adv Med Oncol 2012 Mar;4(2):61-73

Sarah Cannon Research UK, London and University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834011432949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296083PMC
March 2012

Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice.

Cancers (Basel) 2011 Apr 1;3(2):1844-60. Epub 2011 Apr 1.

Sarah Cannon Research Institute, 93 Harley Street, W1G 6AD, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers3021844DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757393PMC
April 2011

Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer.

Cancer 2011 Feb 30;117(4):832-40. Epub 2010 Sep 30.

Prince of Wales Clinical School and Lowy Cancer Research Center, University of New South Wales, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25636DOI Listing
February 2011

Gastric cancer in the era of molecularly targeted agents: current drug development strategies.

J Cancer Res Clin Oncol 2009 Jul 11;135(7):855-66. Epub 2009 Apr 11.

The Medical Professorial Unit, Prince of Wales Medical School, University of New South Wales, Level 1, South Wing, Edmund Blacket Building, Avoca Street, Sydney, NSW, 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-009-0583-7DOI Listing
July 2009

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.

J Clin Oncol 2009 Jun 30;27(16):2692-6. Epub 2009 Mar 30.

Royal Marsden Hospital and Institute of Cancer Research, Drug Development Unit, Sutton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.5081DOI Listing
June 2009

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.

Oncology 2009 23;76(3):151-6. Epub 2009 Jan 23.

Drug Development Unit, Royal Marsden Hospital, London and Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000195884DOI Listing
March 2009

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

Eur J Cancer 2008 Jul 10;44(11):1536-40. Epub 2008 Jun 10.

Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490800330
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2008.04.017DOI Listing
July 2008

Current treatment strategies in elderly patients with metastatic colorectal cancer.

Clin Colorectal Cancer 2007 May;6(7):508-15

Department of Medical Oncology, Royal Marsden Hospital-London and Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/ccc.2007.n.016DOI Listing
May 2007

[A rare case of cholestasis and macrohematuria in a 52-year-old patient].

Med Klin (Munich) 2002 Aug;97(8):480-3

Klinik für Innere Medizin, Zentralkrankenhaus Bremen Ost, Bremen.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00063-002-1183-3DOI Listing
August 2002